Autonomix Medical, Inc. · NASDAQ:AMIX
Autonomix Medical — Investor Presentation (January 2026)
17 slides from Autonomix Medical's investor presentation, Jan 9, 2026
Slide 1: Investor Presentation January 2026
Investor Presentation January 2026
Slide 2: Forward-Looking Statements
AUTONOMIX NASDAQ; AMIX Forward-Looking Statements Al statements contained herein other than stotements of historical fact, Including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-lo
Slide 3: Unleashing the Power of Treatments
AUTONOMIX Unleashing the Power of Treatments Transforming minimally invasive transvascular technology to treat neurological diseases. 120+ Patents Extensive IP Portfolio with 120+ Patents Issued and Pending High Sensitivity to Detect and Differentiate Neural Signals, Enabling Real-Time, High- First-
Slide 4: The Problem
AUTONOMIX NASDAQ; AMIX The Problem Current Technologies Cannot Precisely Target and Treat Overactive Nerves. © Current cardiac sensing technologies cannot detect low amplitude neuronal signals Senses (or maps) 100uV activity while neuronal signaling through the vessel walt is much lower, typically,l
Slide 5: Illuminating the Nervous System with Transvascular Precision-Guided Technology
NASDAQ: AMIX AUTONOMIX \\luminating the Nervous System with Transvascular Precision-Guided Technology >
Slide 6: Enabling Sense, Treat and Verify
AUTONOMIX NASDAQ; AMIX Enabling Sense, Treat and Verify. Potential to Improve Patient Outcomes Through Next-Generation Precision-Guided Treatment @ Sense (Identify) @® Treat (Ablate) (s) Verify (Confirm) Overactive Nerves Target Nerves Treatment Precision Mapping of Neural Advanced Ablation Catheter
Slide 7: Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments
AUTONOMIX NASDAQ; AMIX Unleashing the Power of Precision-Guided, Nerve-Targeted Treatments Summary 1. AS Appiton Speci laptad Cut <5 WV High Sensitivity to Detect and Differentiate Neural Signal Strength ASIC-Powered! Proprietary Sensory Microchip Processes Signal at the Source Signal Travels Only M
Slide 8: PoC Study: First-in-Human Proof-of-Concept
AUTONOMIX PoC 1 Study: First-in-Human Proof-of-Concept Study in Pain Associated With Pancreatic Cancer PoC 1 Initial Phase and Demonstrated Statistically Primary Endpoints: ‘Successtul placementof the catheter determined via Number of Subjects: 20" Clinical Sites: 1 ultrasound imaging, during the ab
Slide 9: PoC Study: Met Efficacy and Safety Objectives
AUTONOMIX NASDAQ; AMIX PoC 1 Study: Met Efficacy and Safety Objectives v w, v a v 4 0 100% of patients (n=16) with femoral access responded to treatment® Pain relief occurred as early as 24 hours post-procedure Pain reduction remained consistently positive at 7 days and 4-6 weeks post-procedure Long
Slide 10: Pain Reduction at 4-6 Weeks & Months
AUTONOMIX Pain Reduction at 4-6 Weeks & 3 Months PANCREATIC CANCER PAIN PoC 1 STUDY: RESPONDING FEMORAL PATIENTS MEAN VAS SCORE OVER TIME Sereening Post-Procedure 7DaysFollow-Up 4.6 Weeks | 3-MonthPost | mete (e24Houra)—(/e4B Hours)” Follow Up | Hoe Anti’! n=9 Be
Slide 11: PoC Study: Subgroup Analysis Shows Pain Relief Observed Across All Disease Stages
AUTONOMIX NASDAQ; AMIX PoC 1 Study: Subgroup Analysis Shows Pain Relief Observed Across All Disease Stages Across all disease stages, responding patients presenting with severe baseline pain experienced rapid, consistent and clinically-meaningful reductions in average pain. Late-Stage Improvement Am
Slide 12: PoC Study: Follow-On Expansion Protocol of Proof-of-Concept Study
AUTONOMIX NASDAQ; AMIX PoC 2 Study: Follow-On Expansion Protocol of Proof-of-Concept Study Evaluation of pain management in additional visceral cancers, earlier stage pancreatic cancer and procedural protocol of Autonomix Sensing & RF Ablation Catheters Refinement to Interventional Pancreatic Cancer
Slide 13: Path to Potential FDA Clearance
AUTONOMIX NASDAQ; AMIX Path to Potential FDA Clearance I 2025 > 2028 : IDE Clinical FDA De Novo FDA Pocstudies |) sicisinus |P|| submission sali Clearance Revenue Generation Model Capital Expenditure Uo Catheter Disposables Annual Software License
Slide 14: Proof-of-Concept in Lead Indication Opens Total Market Opportunity
AUTONOMIX Proof-of-Concept in Lead Indication Opens Total Market Opportunity Potential Future Targets Market Opportunities| ——F | Initial Target ¢ | [$758 $23B
Slide 15: Proven Team with Multiple Successful Exits
AUTONOMIX NASDAQ; AMIX Proven Team with Multiple Successful Exits @ | ©| 6) @ Brad Hauser Jennifer Cook Dr. Robert Schwartz Trent Smith Landy Toth PRESDENT ‘CHEF BUSINESS OFFICER FOUN CCHEFANANCIALOFRICER ‘COFOUNDER cree ecunvEorrICeR CHEE MEDICAL OFFICER Caer recHOLOGY OFFICER a + Mechanica enprecr
Slide 16: Investment Summary
Investment Summary NASDAQ; AMIX “7 AUTONOMIX Unleashing the Power of Nerve-Targeted Treatments Targeting total combined $100 Billion market opportunity 1. nape Transforming the diagnosis and treatment of pain and diseases of the nervous system Significant pain reduction demonstrated in PoC 1 Ongoing
Slide 17: Company
company 9° ‘Betray ase 20 inewWonaaves, 7380, Investor / Media Relations Ne sasnnor7s $ stonemasons autonomix.com
Autonomix Medical — Investor Presentation (January 2026) on 6ix